DUBLIN--(BUSINESS WIRE)--The "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2020" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape.
SYK is a 72 kDa non-receptor tyrosine kinase, which contains two SRC homology 2 (SH2)-domains and a kinase domain, and is most highly expressed by haematopoietic cells. Mammals also express a SYK homologue, ZAP70, which is mostly restricted to T- and NK-lineage cells. SYK-related kinases are also found in invertebrates.
Structure and Signaling of the SYK Receptor
SYK contains two tandem SH2 domains and a C-terminal tyrosine kinase domain. These domains are linked by two linker regions: interdomain A between the two SH2 domains and interdomain B between the C-terminal SH2 domain and the kinase domain. An alternatively spliced form of SYK (known as SYK-B) lacks 23 amino acids of interdomain B, including a nuclear localization signal.
The SYK signalling pathway was initially thought to be restricted to classical immunoreceptors of the adaptive immune response. However, later studies showing that glycoprotein VI (GpVI), a collagen-receptor expressed by platelets, also signals by a similar mechanism2, and that thepetechiated appearance of SYK-deficient embryos was due to a defect in lymphatic vascular development3 provided evidence for the role of SYK outside the adaptive immune response.
Expression
SYK is highly expressed by all haematopoietic lineage cells. Though the expression of SYK is tightly regulated the mechanism of this regulation, or that of the generation of the SYK-B isoform, is poorly understood. Mammals also express the SYK-related molecule ZAP70, the expression of which is mostly confined to the T and NK cell lineages.
Spleen Tyrosine Kinase (SYK) Inhibitors
While SYK inhibitors have shown positive effects in allergy, autoimmune diseases and B-lineage malignancies, the mechanism of their action is incompletely understood. This is in part due to the diverse roles of SYK in immunological functions. As an example, B-cell-mediated antigen presentation and autoantibody formation, Fc-receptor-mediated myeloid cell functions and ?2 integrin-mediated leukocyte activation have all been implicated in the pathogenesis of rheumatoid arthritis and they all have been shown to require SYK.
Spleen Tyrosine Kinase (SYK) Inhibitors Emerging Drugs Chapters
This segment of the Spleen Tyrosine Kinase (SYK) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spleen Tyrosine Kinase (SYK) Inhibitors Emerging Drugs
Cevidoplenib dimesylate: Genosco
The dimesylate salt of cevidoplenib, an orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, cevidoplenib binds to and inhibits the activity of SYK, blocking Fc receptor and B-cell receptor (BCR)-mediated signaling in inflammatory cells, including macrophages, neutrophils, mast cells, natural killer (NK) cells and B cells. This leads to the inhibition of the activation of these inflammatory cells, and the related inflammatory responses and tissue damage.
HMPL-523: Hutchison MediPharma
An orally available inhibitor of spleen tyrosine kinase (Syk), with potential immune-modulating and antineoplastic activities. Upon oral administration of Syk inhibitor HMPL-523, this agent binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation.
Spleen Tyrosine Kinase (SYK) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Spleen Tyrosine Kinase (SYK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Spleen Tyrosine Kinase (SYK) Inhibitors
There are approx. 10+ key companies which are developing the therapies for Spleen Tyrosine Kinase (SYK) Inhibitors. The companies which have their Spleen Tyrosine Kinase (SYK) Inhibitors drug candidates in the most advanced stage, i.e. phase II and Phase II/III include, Rigel Pharmaceuticals, TopiVert etc.
Key Players
- Genosco
- Portola Pharmaceuticals
- GlaxoSmithKline
- FUJIFILM Corporation
- TopiVert
- Takeda Oncology
- Asana BioSciences
Key Products
- CVXL-0074
- Cevidoplenib
- PRT 2761
- GSK 2646264
- Cevidoplenib
- FF 10102 01
- TOP 1630
- Mivavotinib
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/awxzof
